
# Table 1: Evidence-Based DDI Severity Classification Methodology

| Severity Level | Definition | Key Patterns | Evidence Source |
|----------------|------------|--------------|-----------------|
| **Contraindicated** | Life-threatening; concurrent use should be avoided | QT prolongation, serotonin syndrome, fatal bleeding | FDA Black Box Warnings |
| **Major** | May be life-threatening or require medical intervention | Bleeding risk, respiratory depression, organ toxicity | FDA Labels, CHEST Guidelines |
| **Moderate** | May worsen condition or require therapy modification | PK interactions, efficacy changes | Clinical Pharmacology |
| **Minor** | Limited clinical effect | Sedation, GI effects | Package Inserts |

## Pattern-Based Classification Rules

### Contraindicated Patterns (n=18)
- QT prolongation, Torsades de Pointes (FDA Black Box)
- Serotonin syndrome, serotonin toxicity (FDA MAOI Warning)
- Cardiac arrest, ventricular fibrillation (ACC/AHA Guidelines)

### Major Patterns (n=32)
- Bleeding and hemorrhage (CHEST Antithrombotic Guidelines)
- Hyperkalemia (Endocrine Society Guidelines)
- Respiratory depression (FDA Opioid REMS)
- Nephrotoxicity, hepatotoxicity (KDIGO, AASLD Guidelines)

### Moderate Patterns (n=22)
- Serum concentration changes (FDA DDI Guidance)
- CYP enzyme interactions (FDA Drug Interaction Tables)
- Therapeutic efficacy alterations

### Minor Patterns (n=11)
- Sedation, dizziness, nausea
- Theoretical or unlikely interactions
